Deere & Company’s Teva Pharmaceuticals TEVA Stock Holding History

Deere & Company’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-16,382	Closed	-$754K	–	675
2016 Q3	$754K	Hold	16,382	–	–	0.04%	481
2016 Q2	$823K	Hold	16,382	–	–	0.04%	446
2016 Q1	$877K	Hold	16,382	–	–	0.05%	419
2015 Q4	$1.07M	Buy	16,382 +2,484	+18%	+$154K	0.06%	297
2015 Q3	$785K	Sell	13,898 -3,851	-22%	-$250K	0.05%	410
2015 Q2	$1.05M	Hold	17,749	–	–	0.06%	357
2015 Q1	$1.11M	Sell	17,749 -1,175	-6%	-$68.3K	0.06%	309
2014 Q4	$1.09M	Sell	18,924 -26,406	-58%	-$1.47M	0.06%	319
2014 Q3	$2.44M	Sell	45,330 -6,758	-13%	-$358K	0.14%	144
2014 Q2	$2.73M	Buy	52,088 +31,799	+157%	+$1.63M	0.15%	142
2014 Q1	$1.07M	Sell	20,289 -5,368	-21%	-$248K	0.06%	318
2013 Q4	$1.03M	Buy	25,657 +2,184	+9%	+$86K	0.05%	376
2013 Q3	$887K	Buy	23,473 +1,739	+8%	+$67.8K	0.05%	394
2013 Q2	$852K	Buy	+21,734	New	+$846K	0.05%	362

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Deere & Company's TEVA Position: Q4 2016 in Review

Deere & Company sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 16,382 shares — an estimated $754K sold.

Deere & Company first reported a position in TEVA in Q2 2013 and held it in 14 quarters. The position peaked at $2.73M in Q2 2014. 737 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Deere & Company reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Deere & Company sold 16,382 Teva Pharmaceuticals shares in Q4 2016, an estimated $754K.
Deere & Company first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Deere & Company's Teva Pharmaceuticals position peaked at $2.73M in Q2 2014.
737 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Deere & Company's 13F filing for Q4 2016, filed 13 Feb 2017.